Skip to main content

Breadcrumb

  1. Home

HEAL-LAA Clinical Trial

Submitted by rachel on Tue, 03/05/2024 - 15:48
  • Read more about HEAL-LAA Clinical Trial

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Submitted by rachel on Tue, 03/05/2024 - 15:47
  • Read more about Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Submitted by rachel on Tue, 03/05/2024 - 15:47
  • Read more about Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Submitted by rachel on Tue, 03/05/2024 - 15:47
  • Read more about Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Submitted by rachel on Tue, 03/05/2024 - 15:46
  • Read more about Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Submitted by rachel on Tue, 03/05/2024 - 15:46
  • Read more about Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Submitted by rachel on Tue, 02/20/2024 - 17:35
  • Read more about A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate

Submitted by rachel on Tue, 02/13/2024 - 14:34
  • Read more about Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate

PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)

Submitted by rachel on Tue, 02/13/2024 - 14:34
  • Read more about PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Submitted by rachel on Tue, 02/13/2024 - 14:34
  • Read more about Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • …
  • Next page Next
  • Last page Last
Subscribe to